These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24156021)

  • 1. Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.
    Ide H; Kikuchi E; Hasegawa M; Hattori S; Yasumizu Y; Miyajima A; Oya M
    Cancer Med; 2013 Aug; 2(4):488-95. PubMed ID: 24156021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
    Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
    Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer.
    Nagano T; Yasunaga M; Goto K; Kenmotsu H; Koga Y; Kuroda J; Nishimura Y; Sugino T; Nishiwaki Y; Matsumura Y
    Int J Cancer; 2010 Dec; 127(11):2699-706. PubMed ID: 20198621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
    Sasaki E; Tominaga K; Kuwamura H; Watanabe T; Fujiwara Y; Oshitani N; Higuchi K; Arakawa T
    J Gastroenterol; 2007 Oct; 42(10):816-22. PubMed ID: 17940834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
    Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
    Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma.
    Ide H; Kikuchi E; Hasegawa M; Kozakai N; Kosaka T; Miyajima A; Oya M
    BMC Cancer; 2012 Sep; 12():420. PubMed ID: 22998564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
    Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
    Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism.
    Cai JP; Chen W; Hou X; Liang LJ; Hao XY; Yin XY
    Anticancer Drugs; 2013 Nov; 24(10):1020-9. PubMed ID: 23941814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.
    Wada Y; Yoshida K; Suzuki T; Mizuiri H; Konishi K; Ukon K; Tanabe K; Sakata Y; Fukushima M
    Int J Cancer; 2006 Aug; 119(4):783-91. PubMed ID: 16557585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model.
    Abu Lila AS; Moriyoshi N; Fukushima M; Huang CL; Wada H; Ishida T
    Cancer Lett; 2017 Aug; 400():223-231. PubMed ID: 27838412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
    Oguri T; Achiwa H; Bessho Y; Muramatsu H; Maeda H; Niimi T; Sato S; Ueda R
    Lung Cancer; 2005 Sep; 49(3):345-51. PubMed ID: 15993511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer.
    Hasegawa M; Miyajima A; Kosaka T; Yasumizu Y; Tanaka N; Maeda T; Shirotake S; Ide H; Kikuchi E; Oya M
    Int J Cancer; 2012 Jan; 130(2):431-42. PubMed ID: 21351099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.
    Toriumi F; Kubota T; Saikawa Y; Yoshida M; Otani Y; Watanabe M; Kumai K; Kitajima M
    Anticancer Res; 2004; 24(4):2455-63. PubMed ID: 15330198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
    Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Nakaya T; Yonezawa H; Oyama K; Takahashi M; Saito K; Takechi T; Fukushima M; Shirasaka T
    Eur J Cancer; 2003 Nov; 39(16):2387-94. PubMed ID: 14556932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
    Takeda K; Suyama H; Igishi T; Shigeoka Y; Matsumoto S; Yamasaki A; Hashimoto K; Sumikawa T; Morita M; Ueda Y; Shimizu E
    Oncol Rep; 2008 Apr; 19(4):945-51. PubMed ID: 18357380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
    Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
    Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
    Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.